Published mark
Merck & Co.
Merck & Co., Inc.
NYSE: MRK. Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:1aea0f59-381a-4160-9e35-9e60184ed39e
- SEC CIK
- 0000310158
- Website
- www.merck.com Open
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 15, 2026
- Newest evidence
- May 3, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Robert M. DavisSince Feb 24, 2026
- Chair
- Robert M. DavisLead independent: Thomas H. Glocer
- Independent
- 2 / 213 directors published
- Published claims
- 546 distinct sources
- Evidence records
- 300 pinned
- Source conflicts
- 0None open
Built from 6 distinct sources and 30 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
EXECUTIVE APPOINTED
Barbara A. Larson executive of Merck & Co., effective 2026-02-24.
EffectiveEffective Feb 24, 2026E15
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Executive Vice President and Chief Human Resources Officer | Barbara A. Larson | Feb 2026 | current | Source reportedE15 |
| Executive Vice President and Chief Financial Officer | Caroline Litchfield | Feb 2026 | current | Source reportedE17 |
| Senior Vice President, Chief Marketing Officer, Human Health | Chirfi Guindo | Feb 2026 | current | Source reportedE18 |
| Senior Vice President Finance Global Controller | Dalton Smart | Feb 2026 | current | Source reportedE19 |
| Senior Vice President, Human Health Operations | David R. Maraldo | Feb 2026 | current | Source reportedE20 |
| Executive Vice President, Chief Information and Digital Officer | David S. Williams | Feb 2026 | current | Source reportedE21 |
| Executive Vice President, President, Merck Research Laboratories | Dean Li | Feb 2026 | current | Source reportedE22 |
| Executive Vice President and General Counsel | Jennifer Zachary | Feb 2026 | current | Source reportedE23 |
| Senior Vice President and President Merck U.S. Human Health | Johannes J. Oosthuizen | Feb 2026 | current | Source reportedE24 |
| Senior Vice President and President MSD International Human Health | John J. Romanelli | Feb 2026 | current | Source reportedE25 |
| Executive Vice President and President, Merck Animal Health | Richard R. DeLuca, Jr. | Feb 2026 | current | Source reportedE26 |
| Chairman, Chief Executive Officer and President | Robert M. Davis | Feb 2026 | current | Source reportedE27 |
| Executive Vice President and President, Merck Manufacturing Division | Sanat Chattopadhyay | Feb 2026 | current | Source reportedE28 |
| Executive Vice President and Chief Human Resources Officer | Betty D. Larson | Not captured | unknown | Source reportedE16 |
Board of directors
Evidence13 directors published. 2 of 2 with a published determination are independent.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Christine E. Seidman, M.D. | Independent | 2020 | None published | Source reportedE4 |
| Douglas M. Baker, Jr. | Independence not published | 2022 | Audit | Source reportedE5 |
| Inge G. Thulin | Independence not published | 2018 | Compensation and Management DevelopmentCompensation and Management Development; GovernanceGovernance | Source reportedE6 |
| Kathy J. Warden | Independence not published | 2020 | Compensation and Management DevelopmentCompensation and Management Development; GovernanceGovernance | Source reportedE7 |
| Mary Ellen Coe | Independent | 2019 | Compensation and Management Development | Source reportedE4 |
| Pamela J. Craig | Independence not published | 2015 | Audit, chairAudit · Chair; GovernanceGovernance | Source reportedE8 |
| Patricia F. Russo | Independence not published | 1995 | Compensation and Management Development, chairCompensation and Management Development · Chair; GovernanceGovernance | Source reportedE9 |
| Paul B. Rothman, M.D. | Independence not published | 2015 | None published | Source reportedE10 |
| Risa J. Lavizzo-Mourey, M.D. | Independence not published | 2020 | None published | Source reportedE11 |
| Robert M. Davis | Independence not publishedChair | 2021 | None published | Source reportedE3 |
| Stephen L. Mayo, Ph.D. | Independence not published | 2021 | None published | Source reportedE12 |
| Surendralal L. Karsanbhai | Independence not published | 2025 | AuditAudit; GovernanceGovernance | Source reportedE13 |
| Thomas H. Glocer | Independence not publishedLead Independent | 2007 | Compensation and Management DevelopmentCompensation and Management Development; Governance · ChairGovernance, chair | Source reportedE14 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit | Pamela J. Craig | Pamela J. Craig, Douglas M. Baker, Jr., Surendralal L. Karsanbhai | Not described in the published record |
| Audit · Chair; Governance | Not published | Pamela J. Craig | Not described in the published record |
| Audit; Governance | Not published | Surendralal L. Karsanbhai | Not described in the published record |
| Compensation and Management Development | Patricia F. Russo | Patricia F. Russo, Inge G. Thulin, Kathy J. Warden, Mary Ellen Coe, Thomas H. Glocer | Not described in the published record |
| Compensation and Management Development · Chair; Governance | Not published | Patricia F. Russo | Not described in the published record |
| Compensation and Management Development; Governance | Not published | Inge G. Thulin, Kathy J. Warden | Not described in the published record |
| Compensation and Management Development; Governance · Chair | Not published | Thomas H. Glocer | Not described in the published record |
| Governance | Thomas H. Glocer | Thomas H. Glocer, Inge G. Thulin, Kathy J. Warden, Pamela J. Craig, Patricia F. Russo, Surendralal L. Karsanbhai | Not described in the published record |
Committee RecordAudit: Chair Pamela J. Craig; Members Pamela J. Craig (Chair); Douglas M. Baker, Jr.; Surendralal L. Karsanbhai
Committee AppointmentPamela J. Craig: chair, Audit
Committee AppointmentDouglas M. Baker, Jr.: member, Audit
Committee AppointmentSurendralal L. Karsanbhai: member, Audit
Committee RecordCompensation and Management Development: Chair Patricia F. Russo; Members Patricia F. Russo (Chair); Inge G. Thulin; Kathy J. Warden; Mary Ellen Coe; Thomas H. Glocer
Committee AppointmentPatricia F. Russo: chair, Compensation and Management Development
Committee AppointmentInge G. Thulin: member, Compensation and Management Development
Committee AppointmentKathy J. Warden: member, Compensation and Management Development
Committee AppointmentMary Ellen Coe: member, Compensation and Management Development
Committee AppointmentThomas H. Glocer: member, Compensation and Management Development
Committee RecordGovernance: Chair Thomas H. Glocer; Members Thomas H. Glocer (Chair); Inge G. Thulin; Kathy J. Warden; Pamela J. Craig; Patricia F. Russo; Surendralal L. Karsanbhai
Committee AppointmentThomas H. Glocer: chair, Governance
Committee AppointmentInge G. Thulin: member, Governance
Committee AppointmentKathy J. Warden: member, Governance
Committee AppointmentPamela J. Craig: member, Governance
Committee AppointmentPatricia F. Russo: member, Governance
Committee AppointmentSurendralal L. Karsanbhai: member, Governance
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerRobert M. Davis, Chairman, Chief Executive Officer and President, from Feb 24, 2026
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceIndex MembershipS&P 500 (SPX)
Security ListingMRK (NYSE)
Index memberships1 membership attached to a specific security and listing.Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.
SPX
Source reportedAs of Oct 15, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
| Index | Security | Status | Effective | Verification | Source |
|---|---|---|---|---|---|
| S&P 500 (S&P Dow Jones Indices) | NYSE: MRK | current | Mar 4, 1957 | inferred | Slickcharts S&P 500 constituent table (public observation, not S&P DJI license) |
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameMerck & Co., Inc.
Entity StatusPublic listing published
Official Websitehttps://www.merck.com
Published FactUS
Published FactNJ
Published FactHealthcare
Published FactDrug Manufacturers
Published Facthttps://www.merck.com
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Barbara A. LarsonExecutive Vice President and Chief Human Resources Officercompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:23
- Caroline LitchfieldExecutive Vice President and Chief Financial Officercompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:25
- Chirfi GuindoSenior Vice President, Chief Marketing Officer, Human Healthcompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:26
- Dalton SmartSenior Vice President Finance Global Controllercompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:27
- David R. MaraldoSenior Vice President, Human Health Operationscompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:28
- David S. WilliamsExecutive Vice President, Chief Information and Digital Officercompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:29
- Dean LiExecutive Vice President, President, Merck Research Laboratoriescompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:30
- Jennifer ZacharyExecutive Vice President and General Counselcompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:31
- Johannes J. OosthuizenSenior Vice President and President Merck U.S. Human Healthcompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:32
- John J. RomanelliSenior Vice President and President MSD International Human Healthcompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:33
- Richard R. DeLuca, Jr.Executive Vice President and President, Merck Animal Healthcompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:34
- Robert M. DavisChairman, Chief Executive Officer and Presidentcompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:35, company:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:10
- Sanat ChattopadhyayExecutive Vice President and President, Merck Manufacturing Divisioncompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:36
- Betty D. LarsonExecutive Vice President and Chief Human Resources Officercompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:24
- Christine E. Seidman, M.D.Independent Directorcompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:11
- Douglas M. Baker, Jr.Directorcompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:12
- Inge G. ThulinDirectorcompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:13
- Kathy J. WardenDirectorcompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:14
- Mary Ellen CoeIndependent Directorcompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:15
- Pamela J. CraigDirectorcompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:16
- Patricia F. RussoDirectorcompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:17
- Paul B. Rothman, M.D.Directorcompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:18
- Risa J. Lavizzo-Mourey, M.D.Directorcompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:19
- Stephen L. Mayo, Ph.D.Directorcompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:20
- Surendralal L. KarsanbhaiDirectorcompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:21
- Thomas H. GlocerLead Independent Directorcompany:1aea0f59-381a-4160-9e35-9e60184ed39e:leadership_role:22
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 30 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 15, 2026. Cited by 7 Claims.
- E2Merck & Co., Inc. Form 10-K (filed 2026-02-24). SEC filing. Retrieved Aug 29, 2026. Cited by 2 Claims.
- E3sec filing. Published Apr 9, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E4sec proxy. Published Apr 8, 2026. Retrieved May 3, 2026. Cited by 2 Claims.
- E5sec filing. Published Apr 9, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E6sec filing. Published Apr 9, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E7sec filing. Published Apr 9, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E8sec filing. Published Apr 9, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E9sec filing. Published Apr 9, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E10sec filing. Published Apr 9, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E11sec filing. Published Apr 9, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E12sec filing. Published Apr 9, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E13sec filing. Published Apr 9, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E14sec filing. Published Apr 9, 2025. Retrieved May 3, 2026. Cited by 1 Claim.
- E15sec filing. Published Feb 24, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
- E16MRK executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E17sec filing. Published Feb 24, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
- E18sec filing. Published Feb 24, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
- E19sec filing. Published Feb 24, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
- E20sec filing. Published Feb 24, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
- E21sec filing. Published Feb 24, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
- E22sec filing. Published Feb 24, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
- E23sec filing. Published Feb 24, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
- E24sec filing. Published Feb 24, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
- E25sec filing. Published Feb 24, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
- E26sec filing. Published Feb 24, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
- E27sec filing. Published Feb 24, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
- E28sec filing. Published Feb 24, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
- E29board_seats. sp500-board-director-completeness-remediation-2026-05-15. Cited by 17 Claims.
- E30Slickcharts S&P 500 constituent table (public observation, not S&P DJI license). index provider. Retrieved Sep 2, 2026. Cited by 1 Claim.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 15, 2026- Barbara A. Larson executive of Merck & Co., effective 2026-02-24.
- Caroline Litchfield executive of Merck & Co., effective 2026-02-24.
- Chirfi Guindo executive of Merck & Co., effective 2026-02-24.
- Dalton Smart executive of Merck & Co., effective 2026-02-24.
- David R. Maraldo executive of Merck & Co., effective 2026-02-24.
- David S. Williams executive of Merck & Co., effective 2026-02-24.
- Dean Li executive of Merck & Co., effective 2026-02-24.
- Jennifer Zachary executive of Merck & Co., effective 2026-02-24.
- Johannes J. Oosthuizen executive of Merck & Co., effective 2026-02-24.
- John J. Romanelli executive of Merck & Co., effective 2026-02-24.
- Richard R. DeLuca, Jr. executive of Merck & Co., effective 2026-02-24.
- Robert M. Davis executive of Merck & Co., effective 2026-02-24.
- Sanat Chattopadhyay executive of Merck & Co., effective 2026-02-24.
- Surendralal L. Karsanbhai seat on Merck & Co., effective 2025-01-01.
- Audit; Governance committee of Merck & Co., effective 2025-01-01.
- Surendralal L. Karsanbhai member of Audit; Governance, effective 2025-01-01.
- Douglas M. Baker, Jr. seat on Merck & Co., effective 2022-01-01.
- Douglas M. Baker, Jr. member of Audit, effective 2022-01-01.
- Robert M. Davis seat on Merck & Co., effective 2021-01-01.
- Robert M. Davis chairs board Merck & Co., effective 2021-01-01.
- Stephen L. Mayo, Ph.D. seat on Merck & Co., effective 2021-01-01.
- Christine E. Seidman, M.D. seat on Merck & Co., effective 2020-01-01.
- Kathy J. Warden seat on Merck & Co., effective 2020-01-01.
- Risa J. Lavizzo-Mourey, M.D. seat on Merck & Co., effective 2020-01-01.
- Kathy J. Warden member of Compensation and Management Development; Governance, effective 2020-01-01.
- Mary Ellen Coe seat on Merck & Co., effective 2019-01-01.
- Inge G. Thulin seat on Merck & Co., effective 2018-01-01.
- Compensation and Management Development; Governance committee of Merck & Co., effective 2018-01-01.
- Inge G. Thulin member of Compensation and Management Development; Governance, effective 2018-01-01.
- Pamela J. Craig seat on Merck & Co., effective 2015-01-01.
- Paul B. Rothman, M.D. seat on Merck & Co., effective 2015-01-01.
- Audit · Chair; Governance committee of Merck & Co., effective 2015-01-01.
- Pamela J. Craig member of Audit · Chair; Governance, effective 2015-01-01.
- Thomas H. Glocer seat on Merck & Co., effective 2007-01-01.
- Thomas H. Glocer lead independent director of Merck & Co., effective 2007-01-01.
- Compensation and Management Development; Governance · Chair committee of Merck & Co., effective 2007-01-01.
- Thomas H. Glocer member of Compensation and Management Development; Governance · Chair, effective 2007-01-01.
- Patricia F. Russo seat on Merck & Co., effective 1995-01-01.
- Compensation and Management Development · Chair; Governance committee of Merck & Co., effective 1995-01-01.
- Patricia F. Russo member of Compensation and Management Development · Chair; Governance, effective 1995-01-01.